---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-22-000022"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:37:25.583766+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Curis Q3 net loss $13.3M, cuts ~30% of workforce to focus on emavusertib, cash runway into 2025

## Summary
- Net loss of $13.3M ($0.14/shr) vs $11.1M ($0.12/shr) in Q3 2021; revenues $2.8M.
- Plan to reduce workforce by ~30% and reallocate resources to emavusertib pipeline.
- Cash & equivalents $98.7M as of Sep 30; expects cash runway into 2025.
- Updated TakeAim Leukemia data for emavusertib to be presented at ASH 2022 (Dec 10-13).
- FDA has allowed enrollment to resume in TakeAim Lymphoma and monotherapy dose finding of TakeAim Leukemia.

## SEC filing metadata
- accession: 0001108205-22-000022
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820522000022/0001108205-22-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820522000022/cris-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-22-000022
- JSON: https://secwatch.observer/filing/0001108205-22-000022.json
- Plain text: https://secwatch.observer/filing/0001108205-22-000022.txt

## Key facts
- Earnings Releases
  CURIS INC reported third quarter ended September 30, 2022 results: revenue $2.8 million, net income net loss of $13.3 million, EPS $0.14 per share on both a basic and diluted basis.
  - Period: third quarter ended September 30, 2022
  - Revenue: $2.8 million
  - Net income: net loss of $13.3 million
  - EPS: $0.14 per share on both a basic and diluted basis
  - Result: reported results
  source text: to a net loss of $31.8 million, or $0.35 per share on both a basic and diluted basis for the same period in 2021. Revenues, net for the third quarter of 2022 and 2021 were $2.8 million and $3.0 million, respectively. Revenues, net for the nine months ended September 30, 2022 were $7.3 million as compared to $7.5 million for the same period in 2021. Revenues for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820522000022/0001108205-22-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.